Influenza Stocks List

Influenza Stocks Recent News

Date Stock Title
Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
Jul 3 EBS Emergent scores US medical countermeasure contracts worth over $250m
Jul 3 SRPT 1 Soaring Growth Stock to Buy and Hold for 10 Years
Jul 3 SRPT Best Momentum Stocks to Buy for July 3rd
Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
Jul 3 EBS Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? (UPDATED)
Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 3 GILD 5 FDA decisions to watch in the third quarter
Jul 3 SNY Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Jul 2 INO INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
Jul 2 NVAX COVID infections could be seeing a summer surge based on CDC data
Jul 2 EBS Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Jul 2 VRTX Vertex’s cystic fibrosis drug gets FDA priority review
Jul 2 VRTX Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Jul 2 EBS Emergent BioSolutions secures $250M contracts for the U.S. government
Jul 2 NVAX Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Jul 2 EBS Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Influenza

Influenza, commonly known as the flu, is an infectious disease caused by an influenza virus. Symptoms can be mild to severe. The most common symptoms include: high fever, runny nose, sore throat, muscle pains, headache, coughing, sneezing, and feeling tired. These symptoms typically begin two days after exposure to the virus and most last less than a week. The cough, however, may last for more than two weeks. In children, there may be diarrhea and vomiting, but these are not common in adults. Diarrhea and vomiting occur more commonly in gastroenteritis, which is an unrelated disease and sometimes inaccurately referred to as "stomach flu" or the "24-hour flu". Complications of influenza may include viral pneumonia, secondary bacterial pneumonia, sinus infections, and worsening of previous health problems such as asthma or heart failure.Three of the four types of influenza viruses affect people, Type A, Type B, and Type C. Type D has not been known to infect people, but is believed to have the potential to do so. Usually, the virus is spread through the air from coughs or sneezes. This is believed to occur mostly over relatively short distances. It can also be spread by touching surfaces contaminated by the virus and then touching the mouth or eyes. A person may be infectious to others both before and during the time they are showing symptoms. The infection may be confirmed by testing the throat, sputum, or nose for the virus. A number of rapid tests are available; however, people may still have the infection even if the results are negative. A type of polymerase chain reaction that detects the virus's RNA is more accurate.Frequent hand washing reduces the risk of viral spread. Wearing a surgical mask is also useful. Yearly vaccinations against influenza are recommended by the World Health Organization for those at high risk. The vaccine is usually effective against three or four types of influenza. It is usually well-tolerated. A vaccine made for one year may not be useful in the following year, since the virus evolves rapidly. Antiviral drugs such as the neuraminidase inhibitor oseltamivir, among others, have been used to treat influenza. The benefit of antiviral drugs in those who are otherwise healthy do not appear to be greater than their risks. No benefit has been found in those with other health problems.Influenza spreads around the world in yearly outbreaks, resulting in about three to five million cases of severe illness and about 250,000 to 500,000 deaths. About 20% of unvaccinated children and 10% of unvaccinated adults are infected each year. In the northern and southern parts of the world, outbreaks occur mainly in the winter, while around the Equator, outbreaks may occur at any time of the year. Death occurs mostly in the young, the old, and those with other health problems. Larger outbreaks known as pandemics are less frequent. In the 20th century, three influenza pandemics occurred: Spanish influenza in 1918 (~50 million deaths), Asian influenza in 1957 (two million deaths), and Hong Kong influenza in 1968 (one million deaths). The World Health Organization declared an outbreak of a new type of influenza A/H1N1 to be a pandemic in June 2009. Influenza may also affect other animals, including pigs, horses, and birds.

Browse All Tags